Merck And Ridgeback Announce Publication Of Phase 3 Study Of Molnupiravir, An Investigational Oral Antiviral COVID-19 Treatment, In The New England Journal Of Medicine

Published by
The Street

By Business Wire Merck (MRK) – Get Merck & Co., Inc. Report, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced the New England Journal of Medicine has published findings from the Phase 3 MOVe-OUT trial evaluating molnupiravir, an investigational oral antiviral medicine, in non-hospitalized high risk adults with mild to moderate COVID-19. Data from MOVe-OUT demonstrated that early treatment with molnupiravir significantly reduced the risk of hospitalization or death in high risk, unvaccinated adults with COVID-19. Merck is developing molnupiravir i…

Read More

Leave a Reply